Antibiotic Resistant Infection Clinical Trial
Official title:
Modification of Antibiotic Susceptibility Testing: Evaluation of the Impact of This Change on Antibiotic Prescriptions at the Nancy Regional University Hospital
As of 2019, the CA-SFM (Comité de l'Antibiogramme de la Société Française de Microbiologie) recommends that the letter "I" or the term "intermediate" on antibiotic antibiograms. Instead, it is recommended that the term "sensible à forte posologie" or "SFP". These recommendations have been in place since 21/01/2022 at Nancy University Hospital. Pseudomonas aeruginosa is the bacterium most affected by this change, as it has a high proportion of "high dosage" antibiotics. Staphylococcus aureus is the most widely isolated bacterium, and also impacted by the change in antibiotic susceptibility testing. The aim of this change in recommendations is to guarantee the efficacy of the proposed molecules. Main objective Evaluate the impact of the change in antibiogram recommendations in samples positive for Pseudomonas aeruginosa and Staphylococcus aureus on antibiotic therapy (prescribed dosage) Secondary objectives - Evaluate the impact of changing the way antibiograms in Pseudomonas aeruginosa and Staphylococcus aureus on antibiotic therapy (molecule prescribed). - Evaluate the impact of changing the way antibiograms on antibiotic therapy (molecule and dosage prescribed), depending on the strain identified (Pseudomonas aeruginosa or Staphylococcus aureus). - Describe the impact of changing antibiograms in Pseudomonas aeruginosa and Staphylococcus aureus on antibiotic therapy (molecule and dosage prescribed) by department.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
| Recruiting |
NCT02922998 -
CD64 and Antibiotics in Human Sepsis
|
N/A | |
| Completed |
NCT04212403 -
Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)
|
N/A | |
| Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
| Not yet recruiting |
NCT04462133 -
Optimal Tailored Treatment for H. Pylori Infection
|
N/A | |
| Completed |
NCT03535324 -
Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)
|
N/A | |
| Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
| Withdrawn |
NCT04230746 -
Effect of Antibiotics on Urinary Microbiome
|
Early Phase 1 | |
| Active, not recruiting |
NCT03865706 -
Inulin for Infections in the Intensive Care Unit
|
Phase 2 | |
| Not yet recruiting |
NCT06028217 -
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
|
||
| Recruiting |
NCT05391035 -
The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
|
||
| Recruiting |
NCT05224401 -
Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs
|
Phase 3 | |
| Not yet recruiting |
NCT03855709 -
Antibiotic-resistant Bacterial Infection of Hepatic Patients
|
||
| Terminated |
NCT03535272 -
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
|
Phase 3 | |
| Recruiting |
NCT05293483 -
The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
|
||
| Recruiting |
NCT05561504 -
Helicobacter Pylori Local Prevalence and Antibiotic Resistance
|
||
| Recruiting |
NCT03606031 -
Digestive Microbiota Transplant
|
||
| Completed |
NCT01573195 -
Merck IISP Stewardship Grant for Antibiotic Best Practices
|
Phase 4 | |
| Not yet recruiting |
NCT03857295 -
Infections Following NeuroSurgery (INS)
|
||
| Not yet recruiting |
NCT03180983 -
Antibiotic Use in French Nursing Home
|
N/A |